BioLineRx (BLRX) Total Debt Growth (1y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 5.94% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 103.99% |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.07% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -33.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -33.47% |
| Sep 30, 2025 | -63.75% |
| Jun 30, 2025 | -61.97% |
| Mar 31, 2025 | 28.06% |
| Dec 31, 2024 | 37.49% |
| Sep 30, 2024 | 141.02% |
| Jun 30, 2024 | 154.44% |
| Mar 31, 2024 | -10.93% |
| Dec 31, 2023 | -3.88% |
| Sep 30, 2023 | 26.01% |
| Jun 30, 2023 | 1,042.45% |
| Mar 31, 2023 | 467.42% |
| Dec 31, 2022 | 268.81% |
| Sep 30, 2022 | 156.08% |
| Jun 30, 2022 | -76.77% |
| Mar 31, 2022 | -62.77% |
| Dec 31, 2021 | -52.73% |
| Sep 30, 2021 | -45.19% |
| Jun 30, 2021 | -39.41% |
| Mar 31, 2021 | -34.92% |
| Dec 31, 2020 | -31.32% |
| Sep 30, 2020 | -28.90% |
| Jun 30, 2020 | -19.85% |
| Mar 31, 2020 | -11.41% |
| Dec 31, 2019 | -2.77% |
| Sep 30, 2019 | 10,568.60% |
| Jun 30, 2019 | 8,136.70% |
| Mar 31, 2019 | 6,564.66% |
| Dec 31, 2018 | 3,393.20% |
| Sep 30, 2018 | -52.22% |
| Jun 30, 2018 | -46.31% |
| Mar 31, 2018 | -41.41% |
| Dec 31, 2017 | -27.11% |
| Sep 30, 2017 | -33.82% |
| Jun 30, 2017 | -31.42% |
| Mar 31, 2017 | -29.06% |
| Dec 31, 2016 | -0.29% |
| Sep 30, 2016 | -25.68% |